Selenium nanoparticles, a naturally occurring substance, have a significant impact on modern medical treatment. The synthesis of Se NPs utilizing Na2Seo3 salt as precursor materials is reported in this study. The characteristics of the nanoparticles were FTIR and XRD. The FTIR spectrum showed several numbers of a peak at the wavenumber of 3454.51 cm -1 and 1544. 98 cm⁻¹ for O-H stretching, 2902. 87 cm⁻¹ It indicates the vibration of the bonds in the methylene or methyl groups (CH2/CH3), confirming the organic nature of the materials surrounding the nanoselenium, 1635. 64 cm⁻¹ This deep, sharp peak is crucial, It denotes the existence of an amide bond in proteins or a carbonyl group in organic acids, the XRD peaks at 2θ=17.86 [426.89], 21.68[764.15], 27.63[668.59], 36.51[298.07] from this data can average particle size of Se NPs was calculated to be 5.135 nm. Finding the dose-dependent impact of selenium on the growth of the MCF-7, AMJ13, and NHF cell lines was the aim of the current study. The cytotoxicity of the selenium nanoparticles was examined using breast cancer cell lines. The Methyl thiazolyltetrazolium (MTT) assay was used to determine the median inhibitory concentration (IC50). The IC50 values for selenium were 18.52 µg/mL for AMJ-13, 6.382 µg/mL for MCF-7, and 273.1 µg/mL for the normal NHF cell line.First. At varying concentrations, selenium hindered the cells' ability to proliferate of 100, 50, 25, 12.5, 6.2, 3.1 ug/mL for AMJ-13 (63.35%, 40.11%, 31.3%, 27.2%, 17.41%, and 13.91%). Respectively and for MCF-7 at the same concentration (70.75, 64.41, 50.56, 47.14, 37.7 and 27.68). To sum up, Selenium NPs displays strong cytotoxicity against the AMJ13 and MCF-7 breast cancer cell lines. It is possible to draw the conclusion that selenium has a dose-dependent impact on the growth of MCF-7, AMJ13, and NHF. Furthermore, apoptosis and morphological alterations greatly intensify the growth inhibition.
Keywords
Breast CancerSelenium NanoparticlesIC50MTT Cell LinesAMJ-13MCF-7
References
H. N. Ali, A. M. S. Almohaidi, and M. W. M. Alzubadiy, “Effect of green selenium nanosynthesis on Staphylococcus aureus,” in Proc. Int. Conf. Applied Innovation in IT, vol. 13, no. 2, pp. 873-879, Jun. 2025.
C. Wen, X. He, J. Zhang, G. Liu, and X. Xu, “A review on selenium-enriched proteins: Preparation, purification, identification, bioavailability, bioactivities and application,” Food Funct., vol. 13, no. 10, pp. 5498-5514, 2022.
T. Zhang, M. Qi, Q. Wu, P. Xiang, D. Tang, and Q. Li, “Recent research progress on the synthesis and biological effects of selenium nanoparticles,” Front. Nutr., vol. 10, p. 1183487, 2023, [Online]. Available: https://doi.org/10.3389/fnut.2023.1183487.
C. Ferro, H. F. Florindo, and H. A. Santos, “Selenium nanoparticles for biomedical applications: From development and characterization to therapeutics,” Adv. Healthcare Mater., vol. 10, no. 16, p. 2100598, 2021.
A. L. E. M. Eltouny, “Cancer: Is it really incurable? A review,” EC Cancer, vol. 2, pp. 1-10, 2025.
O. A. Abozaid, L. A. Rashed, S. M. El-Sonbaty, A. I. Abu-Elftouh, and E. S. Ahmed, “Mesenchymal stem cells and selenium nanoparticles synergize with low dose of gamma radiation to suppress mammary gland carcinogenesis via regulation of tumor microenvironment,” Biol. Trace Elem. Res., vol. 201, no. 1, pp. 338-352, 2023.
E. G. Varlamova, “Selenium-containing compounds in breast cancer therapy,” Biol. Trace Elem. Res., pp. 1-24, 2026.
K. Anu, G. Singaravelu, K. Murugan, and G. Benelli, “Green synthesis of selenium nanoparticles using garlic cloves (Allium sativum): Biophysical characterization and cytotoxicity on Vero cells,” J. Cluster Sci., vol. 28, no. 1, pp. 551-563, 2017.
M. I. Salman, A. M. Al-Shammari, and M. A. Emran, “3-Dimensional coculture of breast cancer cell lines with adipose tissue-derived stem cells reveals the efficiency of oncolytic Newcastle disease virus infection via labeling technology,” Front. Mol. Biosci., vol. 9, p. 986, 2022.
Y. H. Ali, S. N. Muslim, and I. H. Hamzah, “Assessing the efficacy of dextran and dextransucrase in modulating MCF-7 breast cancer cell activity,” Al-Kufa Univ. J. Biol., vol. 15, no. 3, pp. 20-27, 2023.
A. M. Al-Shammari and M. I. Salman, “Antimetastatic and antitumor activities of oncolytic NDV AMHA1 in a 3D culture model of breast cancer,” Front. Mol. Biosci., vol. 11, p. 1331369, 2024.
Z. T. Khodair et al., “Synthesis of copper oxide nanoparticles (CuO-NPs) and its evaluation of antibacterial activity against P. aeruginosa biofilm genes,” in AIP Conf. Proc., vol. 2190, no. 1, p. 020006, Dec. 2019.
J. W. Oh, M. Muthu, S. S. C. Pushparaj, and J. Gopal, “Anticancer therapeutic effects of green tea catechins (GTCs) when integrated with antioxidant natural components,” Molecules, vol. 28, no. 5, p. 2151, 2023.
S. Anjum et al., “Selenium nanoparticles in cancer therapy: Unveiling cytotoxic mechanisms and therapeutic potential,” Cancer Rep., vol. 8, no. 6, p. e70210, 2025.
L. V. Belskaya and E. I. Dyachenko, “Oxidative stress in breast cancer: A biochemical map of reactive oxygen species production,” Curr. Issues Mol. Biol., vol. 46, no. 5, pp. 4646-4687, 2024.
Z. Chen, H. Lai, L. Hou, and T. Chen, “Rational design and action mechanisms of chemically innovative organoselenium in cancer therapy,” Chem. Commun., vol. 56, no. 2, pp. 179-196, 2020.
B. R. Stockwell, X. Jiang, and W. Gu, “Emerging mechanisms and disease relevance of ferroptosis,” Trends Cell Biol., vol. 30, no. 6, pp. 478-490, 2020.
B. Wang et al., “ROS-induced lipid peroxidation modulates cell death outcome: Mechanisms behind apoptosis, autophagy, and ferroptosis,” Arch. Toxicol., vol. 97, no. 6, pp. 1439-1451, 2023.
